Saturday, December 28, 2013 1:24:10 PM
* Opening German Clinics for L.
*Opening European Clinics for Direct.
* Initial data regarding Direct's efficacy on first 2 or 3 patients.
* Recommendations from Review board on DCVax-L.
A few things we know/believe from various sources.
1. Germany is still gearing up for opening its clinics/manufacturing/quality control/compassionate use for DCVAX-L -- should happen any day.
2. The Brits are up and running their DCVAX-L phase III trial, manufacturing and parallel compassionate use program.
3. Sarah Cannon -- and perhaps MD Anderson's European sites -- are preparing to begin DCVAX-Direct trials.
4. The equivalent of a less potent version of DCVAX-Direct was used successfully on 10 Humans -- (not just mice)--patients in the Triozzi study way back in 2000, and an amazing 6 out of ten very sick patients had tumor reduction and signs of immunity. In that study, Triozzi amazingly held off on using that product at that time in favor of scientists developing a more "potent" version through development (think about that for a moment). 11-13 years later, NWBO announced through patents, press releases and presentations that it has that more potent version.
5. DCVax-L reached its first interim event juncture when NWBO thought it would. Because NWBO is using a better trial design in phase 3 that allows them to exclude post radiation patients with concurrent tumor progression, we might, might, might submit that the first event juncture and timely prediction thereof was predicated almost exclusively on control arm events. Whereby the trial arm might benefit far more than the control arm ( as anticipated based upon our understanding of past preclinical, clinical and third party experience/results) from the synergistic advances of improved near total tumor resection, chemotherapy/radiation and undetectable tumor progression in the selected patient population at the moment DCVAX-L/placebo treatment is initiated.
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM
Avant Technologies Welcomes Back Former CEO with Eye Toward Future Growth and Expansion • AVAI • Jul 17, 2024 8:00 AM